# Linagliptin

## Trajenta 5mg

##### 

| Title              | Content                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | OTRAJ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Indications        | Management of type 2 diabetes mellitus (noninsulin dependent， NIDDM) as an adjunct to diet and exercise as monotherapy or in combination with other antidiabetic agents.                                                                                                                                                                                                                                                                                                                                         |
| Dosing             | 5 mg once daily.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Contraindications  | Hypersensitivity to linagliptin or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | >10%: Endocrine & metabolic: Hypoglycemia (combined with metformin/sulfonylurea [15%]， metformin [<1%]， pioglitazone [<1%]; monotherapy [<1%]) Central nervous system: Headache (6%) Endocrine & metabolic: Hyperuricemia (3%)， lipids increased (3%)， triglycerides increased (2%)， weight gain (2%) Neuromuscular & skeletal: Arthralgia (6%)， back pain (6%) Respiratory: Nasopharyngitis (6%)， cough (2%) <1% (Limited to important or life-threatening): Angioedema， hypersensitivity， pancreatitis |
| Pregnancy          | No (limited) human data – animal data suggest low risk                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

